Stapleton 2013.

Methods	BUPROPION Randomized controlled trial Setting: Smoking cessation clinics, UK Recruitment: People attending smoking cessation clinics
Participants	1071 daily smokers; 47% M, av age 41, av CPD 20, >25% history of depression
Interventions	1. Bupropion for 8 weeks, started prior to TQD (exact period NS), 150 mg/d for first 6d, then 300 mg for remainder 2. Bupropion (as above) + NRT (choice of single product, 12 weeks started on TQD, dosage determined on individual basis) 3. NRT only (as above) All groups: 7 weekly behavioural support sessions as per standard service protocol. Mainly group, 60‐90 mins each
Outcomes	Prolongued abstinence at 6m Validation: CO < 10 ppm
Notes	Funding: Department of Health for England. Study medication provided free of charge by Pfizer UK, GSK UK and Novartis UK.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computerized. “Randomization and packaging was organized by an independent statistician at the host site.”
Allocation concealment (selection bias)	Low risk	“On enrolment, participants selected their envelope from a large batch and signed it before breaking the seal to reveal their allocation.”
Blinding (performance bias and detection bias) All outcomes	High risk	Open label, no blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	61.5% followed up at both 1 and 6m, no significant difference between groups. Prolonged abstinence only imputed for 16% of total.